Trevi Therapeutics (TRVI) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Raymond James Reiterates Strong Buy Rating on Trevi Therapeutics (TRVI)
March 19, 2025 7:22 AM EDTRaymond James analyst Ryan Deschner reiterated a Strong Buy rating and $29.00 price target on Trevi Therapeutics (NASDAQ: TRVI).
The analyst comments "We remain Strong Buy rated on TRVI following 4Q24 earnings. Our bullish thesis that Haduvio could potentially become the go-to... More
